vs
FactSet（FDS）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是FactSet的1.0倍（$622.0M vs $607.6M），Royalty Pharma plc净利率更高（34.4% vs 25.1%，领先9.3%），FactSet同比增速更快（6.9% vs 4.8%），过去两年FactSet的营收复合增速更高（5.5% vs 4.6%）
FactSet是总部位于美国康涅狄格州诺沃克的金融数据与软件企业，为客户提供一体化数据及软件解决方案。2024财年，公司年度订阅价值与专业服务营收合计22亿美元，当前总市值约170亿美元。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
FDS vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.0倍
$607.6M
营收增速更快
FDS
高出2.1%
4.8%
净利率更高
RPRX
高出9.3%
25.1%
两年增速更快
FDS
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $607.6M | $622.0M |
| 净利润 | $152.6M | $214.2M |
| 毛利率 | 52.6% | — |
| 营业利润率 | 31.6% | 62.4% |
| 净利率 | 25.1% | 34.4% |
| 营收同比 | 6.9% | 4.8% |
| 净利润同比 | 1.7% | 2.9% |
| 每股收益（稀释后） | $4.06 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FDSRPRX
| Q4 25 | $607.6M | $622.0M | ||
| Q3 25 | $596.9M | $609.3M | ||
| Q2 25 | $585.5M | $578.7M | ||
| Q1 25 | $570.7M | $568.2M | ||
| Q4 24 | $568.7M | $593.6M | ||
| Q3 24 | $562.2M | $564.7M | ||
| Q2 24 | $552.7M | $537.3M | ||
| Q1 24 | $545.9M | $568.0M |
净利润FDSRPRX
| Q4 25 | $152.6M | $214.2M | ||
| Q3 25 | $153.6M | $288.2M | ||
| Q2 25 | $148.5M | $30.2M | ||
| Q1 25 | $144.9M | $238.3M | ||
| Q4 24 | $150.0M | $208.2M | ||
| Q3 24 | $89.5M | $544.0M | ||
| Q2 24 | $158.1M | $102.0M | ||
| Q1 24 | $140.9M | $4.8M |
毛利率FDSRPRX
| Q4 25 | 52.6% | — | ||
| Q3 25 | 51.6% | — | ||
| Q2 25 | 52.1% | — | ||
| Q1 25 | 52.8% | — | ||
| Q4 24 | 54.5% | — | ||
| Q3 24 | 54.1% | — | ||
| Q2 24 | 55.3% | — | ||
| Q1 24 | 53.3% | — |
营业利润率FDSRPRX
| Q4 25 | 31.6% | 62.4% | ||
| Q3 25 | 29.7% | 70.1% | ||
| Q2 25 | 33.2% | 36.3% | ||
| Q1 25 | 32.5% | 94.0% | ||
| Q4 24 | 33.6% | 60.9% | ||
| Q3 24 | 22.7% | — | ||
| Q2 24 | 36.6% | 50.2% | ||
| Q1 24 | 33.3% | -13.0% |
净利率FDSRPRX
| Q4 25 | 25.1% | 34.4% | ||
| Q3 25 | 25.7% | 47.3% | ||
| Q2 25 | 25.4% | 5.2% | ||
| Q1 25 | 25.4% | 41.9% | ||
| Q4 24 | 26.4% | 35.1% | ||
| Q3 24 | 15.9% | 96.3% | ||
| Q2 24 | 28.6% | 19.0% | ||
| Q1 24 | 25.8% | 0.8% |
每股收益（稀释后）FDSRPRX
| Q4 25 | $4.06 | $0.49 | ||
| Q3 25 | $4.03 | $0.67 | ||
| Q2 25 | $3.87 | $0.07 | ||
| Q1 25 | $3.76 | $0.55 | ||
| Q4 24 | $3.89 | $0.46 | ||
| Q3 24 | $2.33 | $1.21 | ||
| Q2 24 | $4.09 | $0.23 | ||
| Q1 24 | $3.65 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $292.7M | $618.7M |
| 总债务越低越好 | $1.4B | $9.0B |
| 股东权益账面价值 | $2.2B | $9.7B |
| 总资产 | $4.2B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.63× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资FDSRPRX
| Q4 25 | $292.7M | $618.7M | ||
| Q3 25 | $355.1M | $938.9M | ||
| Q2 25 | $364.0M | $631.9M | ||
| Q1 25 | $287.0M | $1.1B | ||
| Q4 24 | $358.8M | $929.0M | ||
| Q3 24 | $492.6M | $950.1M | ||
| Q2 24 | $522.0M | $1.8B | ||
| Q1 24 | $450.2M | $843.0M |
总债务FDSRPRX
| Q4 25 | $1.4B | $9.0B | ||
| Q3 25 | $1.4B | $8.9B | ||
| Q2 25 | $1.4B | $8.0B | ||
| Q1 25 | $1.5B | $7.6B | ||
| Q4 24 | $1.4B | $7.6B | ||
| Q3 24 | $1.4B | $7.6B | ||
| Q2 24 | $1.4B | $7.6B | ||
| Q1 24 | $1.5B | $6.1B |
股东权益FDSRPRX
| Q4 25 | $2.2B | $9.7B | ||
| Q3 25 | $2.2B | $9.6B | ||
| Q2 25 | $2.2B | $9.5B | ||
| Q1 25 | $2.1B | $9.8B | ||
| Q4 24 | $2.0B | $10.3B | ||
| Q3 24 | $1.9B | $10.3B | ||
| Q2 24 | $1.9B | $9.8B | ||
| Q1 24 | $1.8B | $9.9B |
总资产FDSRPRX
| Q4 25 | $4.2B | $19.6B | ||
| Q3 25 | $4.3B | $19.3B | ||
| Q2 25 | $4.3B | $18.3B | ||
| Q1 25 | $4.2B | $17.6B | ||
| Q4 24 | $4.0B | $18.2B | ||
| Q3 24 | $4.1B | $18.0B | ||
| Q2 24 | $4.0B | $17.7B | ||
| Q1 24 | $4.0B | $16.1B |
负债/权益比FDSRPRX
| Q4 25 | 0.63× | 0.92× | ||
| Q3 25 | 0.63× | 0.93× | ||
| Q2 25 | 0.66× | 0.84× | ||
| Q1 25 | 0.72× | 0.78× | ||
| Q4 24 | 0.68× | 0.74× | ||
| Q3 24 | 0.71× | 0.74× | ||
| Q2 24 | 0.76× | 0.78× | ||
| Q1 24 | 0.83× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $121.3M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $90.4M | — |
| 自由现金流率自由现金流/营收 | 14.9% | — |
| 资本支出强度资本支出/营收 | 5.1% | — |
| 现金转化率经营现金流/净利润 | 0.79× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $647.4M | — |
8季度趋势，按日历期对齐
经营现金流FDSRPRX
| Q4 25 | $121.3M | $827.1M | ||
| Q3 25 | $212.1M | $702.6M | ||
| Q2 25 | $253.8M | $364.0M | ||
| Q1 25 | $174.0M | $596.1M | ||
| Q4 24 | $86.4M | $742.5M | ||
| Q3 24 | $163.2M | $703.6M | ||
| Q2 24 | $238.2M | $658.2M | ||
| Q1 24 | $143.8M | $664.6M |
自由现金流FDSRPRX
| Q4 25 | $90.4M | — | ||
| Q3 25 | $178.1M | — | ||
| Q2 25 | $228.6M | — | ||
| Q1 25 | $150.2M | — | ||
| Q4 24 | $60.5M | — | ||
| Q3 24 | $137.2M | — | ||
| Q2 24 | $216.9M | — | ||
| Q1 24 | $121.9M | — |
自由现金流率FDSRPRX
| Q4 25 | 14.9% | — | ||
| Q3 25 | 29.8% | — | ||
| Q2 25 | 39.0% | — | ||
| Q1 25 | 26.3% | — | ||
| Q4 24 | 10.6% | — | ||
| Q3 24 | 24.4% | — | ||
| Q2 24 | 39.2% | — | ||
| Q1 24 | 22.3% | — |
资本支出强度FDSRPRX
| Q4 25 | 5.1% | — | ||
| Q3 25 | 5.7% | — | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 4.5% | — | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 3.9% | — | ||
| Q1 24 | 4.0% | — |
现金转化率FDSRPRX
| Q4 25 | 0.79× | 3.86× | ||
| Q3 25 | 1.38× | 2.44× | ||
| Q2 25 | 1.71× | 12.06× | ||
| Q1 25 | 1.20× | 2.50× | ||
| Q4 24 | 0.58× | 3.57× | ||
| Q3 24 | 1.82× | 1.29× | ||
| Q2 24 | 1.51× | 6.45× | ||
| Q1 24 | 1.02× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FDS
| Americas Segment | $399.7M | 66% |
| EMEA Segment | $149.1M | 25% |
| Asia Pacific Segment | $62.2M | 10% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
